$SBFM
Sunshine Biopharma Inc. Stock $sbfm

$sbfm Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000168316823003121 Filed on May 10, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$5.561M	$4.894M	$122.7K
YoY Change	3599.67%	3890.26%	206.17%
Cost Of Revenue	$3.608M	$3.066M	$59.85K
YoY Change	4731.24%	5022.69%	223.16%
Gross Profit	$1.953M	$1.828M	$62.80K
YoY Change	2482.18%	2811.02%	191.55%
Gross Profit Margin	35.12%	37.35%	51.2%
Selling, General & Admin	$3.076M	$3.785M	$921.4K
YoY Change	325.28%	310.79%	-18.26%
% of Gross Profit	157.5%	207.04%	1467.2%
Research & Development	$368.6K	$432.9K	$361.7K
YoY Change	702.22%	19.71%	116.83%
% of Gross Profit	18.87%	23.68%	575.88%
Depreciation & Amortization	$34.88K	$34.71K	$3.110K
YoY Change	1425.01%	1016.08%	-2.2%
% of Gross Profit	1.79%	1.9%	4.95%
Operating Expenses	$3.444M	$4.218M	$1.286M
YoY Change	7396.49%	227.95%	-0.85%
Operating Profit	-$989.6K	-$1.829M	-$1.223M
YoY Change	42.23%	49.5%	-4.1%
Interest Expense	$27.60K	$41.08K	-$12.87K
YoY Change		-419.15%	-74.12%
% of Operating Profit
Other Income/Expense, Net	$175.2K	$172.8K	-$12.87K
YoY Change	11.64%	-1442.82%
Pretax Income	-$814.4K	-$1.656M	-$1.236M
YoY Change	51.14%	33.97%	-80.01%
Income Tax	$87.68K	$46.27K	$0.00
% Of Pretax Income
Net Earnings	-$902.1K	-$1.702M	-$1.236M
YoY Change	67.41%	37.71%	-80.01%
Net Earnings / Revenue	-16.22%	-34.79%	-1007.93%
Basic Earnings Per Share	-$0.02	-$7.73
Diluted Earnings Per Share	-$0.04	-$0.08	-$234.5K
COMMON SHARES
Basic Shares Outstanding	22.14M shares	22.59M shares
Diluted Shares Outstanding	25.35M shares	22.04M shares	5.273M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$19.73M	$19.29M	$13.18M
YoY Change	-52.72%	46.42%	633.48%
Cash & Equivalents	$19.73M	$19.29M	$13.18M
Short-Term Investments
Other Short-Term Assets	$107.0K	$152.3K	$46.22K
YoY Change	90.6%	229.42%	148.76%
Inventory	$4.251M	$3.710M	$181.5K
Prepaid Expenses	$107.0K	$152.3K
Receivables	$2.011M	$1.790M	$20.00
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$26.10M	$24.95M	$13.41M
YoY Change	-37.84%	86.1%	627.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$366.7K	$368.0K	$3.980K
YoY Change	22231.55%	9147.04%	-76.07%
Goodwill
YoY Change
Intangibles	$1.234M	$948.2K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$2.311M	$2.044M	$3.970K
YoY Change	140662.06%	51396.25%	-76.13%
TOTAL ASSETS
Total Short-Term Assets	$26.10M	$24.95M	$13.41M
Total Long-Term Assets	$2.311M	$2.044M	$3.970K
Total Assets	$28.41M	$26.99M	$13.41M
YoY Change	-32.34%	101.29%	621.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.760M	$2.736M	$95.23K
YoY Change	1581.05%	2773.21%	-35.9%
Accrued Expenses	$122.2K	$121.3K	$0.00
YoY Change			-100.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.660M	$6.906M	$95.23K
YoY Change	4351.82%	7151.6%	-88.99%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$596.9K	$613.1K
YoY Change
Total Long-Term Liabilities	$639.9K	$656.2K	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.660M	$6.906M	$95.23K
Total Long-Term Liabilities	$639.9K	$656.2K	$0.00
Total Liabilities	$5.300M	$7.562M	$95.23K
YoY Change	4963.07%	7840.64%	-96.76%
SHAREHOLDERS EQUITY
Retained Earnings	-$62.00M	-$61.10M
YoY Change	80.09%
Common Stock	$25.75K	$22.14K
YoY Change	36.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$23.11M	$19.43M	$13.31M
YoY Change
Total Liabilities & Shareholders Equity	$28.41M	$26.99M	$13.41M
YoY Change	-32.34%	101.29%	621.53%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$902.1K	-$1.702M	-$1.236M
YoY Change	67.41%	37.71%	-80.01%
Depreciation, Depletion And Amortization	$34.88K	$34.71K	$3.110K
YoY Change	1425.01%	1016.08%	-2.2%
Cash From Operating Activities	-$3.778M	-$1.850M	-$1.304M
YoY Change	558.42%	41.86%	338.6%
INVESTING ACTIVITIES
Capital Expenditures	$294.2K	$178.4K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$34.76K	$32.09K
YoY Change
Cash From Investing Activities	-$259.5K	-$146.3K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.058M	-$538.3K	12.44M
YoY Change	-86.07%	-104.33%	1028.65%
NET CHANGE
Cash From Operating Activities	-3.778M	-$1.850M	-1.304M
Cash From Investing Activities	-259.5K	-$146.3K	$0.00
Cash From Financing Activities	4.058M	-$538.3K	12.44M
Net Change In Cash	20.45K	-$2.535M	11.13M
YoY Change	-99.93%	-122.77%	1283.66%
FREE CASH FLOW
Cash From Operating Activities	-$3.778M	-$1.850M	-$1.304M
Capital Expenditures	$294.2K	$178.4K
Free Cash Flow	-$4.072M	-$2.029M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	4th Floor
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001402328
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-41282
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	SUNSHINE BIOPHARMA, INC.
CY2023Q1	dei	Entity Address Address Line3 EntityAddressAddressLine3	Pointe-Claire
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Quebec
CY2023Q1	dei	Entity Address Country EntityAddressCountry	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	H9R 0A5
CY2023Q1	dei	City Area Code CityAreaCode	(514)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	426-6161
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	22139921	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19294218	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21826437	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1790480	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1912153	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	3709987	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3289945	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	152262	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	283799	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	24946947	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	27312334	usd
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	CO
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-5566275
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	6500 Trans-Canada Highway
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	46270	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	368032	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	394249	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	948240	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	776856	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	728129	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	760409	usd
CY2023Q1	us-gaap	Assets Assets	26991348	usd
CY2022Q4	us-gaap	Assets Assets	29243848	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2736154	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2802797	usd
CY2023Q1	SBFM	Earnout Payable EarnoutPayable	3632000	usd
CY2022Q4	SBFM	Earnout Payable EarnoutPayable	3632000	usd
CY2023Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	416245	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	373191	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	121303	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	123026	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6905702	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6931014	usd
CY2023Q1	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	43032	usd
CY2022Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	43032	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	613136	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	642232	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	656168	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	685264	usd
CY2023Q1	us-gaap	Liabilities Liabilities	7561870	usd
CY2022Q4	us-gaap	Liabilities Liabilities	7616278	usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	1000	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	1000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22139921	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22139921	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22585632	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22585632	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	22139	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	22585	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	80335376	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	80841752	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	173007	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	161847	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-61102044	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-59399614	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	19429478	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	21627570	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	26991348	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29243848	usd
CY2023Q1	us-gaap	Revenues Revenues	4894053	usd
CY2022Q1	us-gaap	Revenues Revenues	122645	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	3065931	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	59845	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	1828122	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	62800	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	169750	usd
CY2022Q1	us-gaap	Professional Fees ProfessionalFees	73800	usd
CY2023Q1	SBFM	Consulting Expense ConsultingExpense	131615	usd
CY2022Q1	SBFM	Consulting Expense ConsultingExpense	5498	usd
CY2023Q1	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	100000	usd
CY2022Q1	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	50000	usd
CY2023Q1	us-gaap	Legal Fees LegalFees	107449	usd
CY2022Q1	us-gaap	Legal Fees LegalFees	136225	usd
CY2023Q1	us-gaap	Marketing Expense MarketingExpense	127913	usd
CY2022Q1	us-gaap	Marketing Expense MarketingExpense	95040	usd
CY2023Q1	SBFM	Office Expense OfficeExpense	482458	usd
CY2022Q1	SBFM	Office Expense OfficeExpense	282505	usd
CY2023Q1	SBFM	Patenting Fees PatentingFees	6308	usd
CY2022Q1	SBFM	Patenting Fees PatentingFees	8334	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	432925	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	361652	usd
CY2023Q1	us-gaap	Salaries And Wages SalariesAndWages	2000257	usd
CY2022Q1	us-gaap	Salaries And Wages SalariesAndWages	270000	usd
CY2023Q1	SBFM	Taxes Taxes	63718	usd
CY2022Q1	SBFM	Taxes Taxes	0	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	34710	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3110	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3657103	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1286164	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1828981	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1223364	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	15	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-9	usd
CY2023Q1	us-gaap	Interest Income Debt Securities Operating InterestIncomeDebtSecuritiesOperating	213881	usd
CY2022Q1	us-gaap	Interest Income Debt Securities Operating InterestIncomeDebtSecuritiesOperating	3	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	41075	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	12864	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	172821	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-12870	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1656160	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1236234	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1702430	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1236234	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	11160	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	1007	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1691270	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1235227	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22036272	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5272856	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1702430	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1236234	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	34710	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3110	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax	-0	usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax	-9	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-135891	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-7774	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	417318	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	73865	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-129849	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	9007	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-73661	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	52292	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	42853	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	usd
CY2023Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	usd
CY2022Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-48287	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1850106	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1304208	usd
CY2023Q1	SBFM	Reduction In Right Of Use Asset ReductionInRightOfUseAsset	32934	usd
CY2022Q1	SBFM	Reduction In Right Of Use Asset ReductionInRightOfUseAsset	0	usd
CY2023Q1	SBFM	Cash Given From Acquisition CashGivenFromAcquisition	1135	usd
CY2022Q1	SBFM	Cash Given From Acquisition CashGivenFromAcquisition	-0	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	178395	usd
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	293	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-146303	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14436673	usd
CY2023Q1	SBFM	Purchase Of Treasury Stock PurchaseOfTreasuryStock	506822	usd
CY2022Q1	SBFM	Purchase Of Treasury Stock PurchaseOfTreasuryStock	99000	usd
CY2023Q1	SBFM	Payment For Lease Liability PaymentForLeaseLiability	31477	usd
CY2022Q1	SBFM	Payment For Lease Liability PaymentForLeaseLiability	-0	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	-0	usd
CY2022Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1900000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-538299	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12437673	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21826437	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2045167	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2534708	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	11133465	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2489	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1007	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19294218	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13177625	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	15271	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	211662	usd
CY2022Q1	SBFM	Common Stock And Prefunded Warrants Issued In Public Offerings CommonStockAndPrefundedWarrantsIssuedInPublicOfferings	13614270	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	822403	usd
CY2022Q1	SBFM	Preferred Stock Purchased From Related Party Value PreferredStockPurchasedFromRelatedPartyValue	99000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1235227	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	14549335	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	21627570	usd
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	506822	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1691270	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	19429478	usd
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.10
CY2021	SBFM	Stock Issued During Period Shares StockIssuedDuringPeriodShares	859114	shares
CY2023Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	2000000	usd
CY2023Q1	us-gaap	Dividends Dividends	0	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	728129	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	121303	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	613136	usd
CY2023Q1	SBFM	Lessee Operating Lease Remaining Lease Term1 LesseeOperatingLeaseRemainingLeaseTerm1	6 years 9 months
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06	pure
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	91654	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	115978	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	116166	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	110028	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	103636	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	196976	usd
CY2023Q1	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	820000	usd
CY2022Q1	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	270000	usd
CY2023Q1	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	100000	usd
CY2022Q1	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	50000	usd

Files In Submission

Name	View Source	Status
0001683168-23-003121-index-headers.html	Edgar Link	pending
0001683168-23-003121-index.html	Edgar Link	pending
0001683168-23-003121.txt	Edgar Link	pending
0001683168-23-003121-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sbfm-20230331.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
sunshine_ex3101.htm	Edgar Link	pending
sunshine_ex3102.htm	Edgar Link	pending
sunshine_ex3201.htm	Edgar Link	pending
sunshine_i10q-033123.htm	Edgar Link	pending
sbfm-20230331_cal.xml	Edgar Link	unprocessable
sbfm-20230331_def.xml	Edgar Link	unprocessable
sbfm-20230331_pre.xml	Edgar Link	unprocessable
sbfm-20230331_lab.xml	Edgar Link	unprocessable
sunshine_i10q-033123_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SBFM
Sunshine Biopharma Inc. Stock $sbfm

2023 Q2 Form 10-Q Financial Statement

#000168316823003121 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SBFM Sunshine Biopharma Inc. Stock $sbfm

2023 Q2 Form 10-Q Financial Statement

#000168316823003121 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SBFM
Sunshine Biopharma Inc. Stock $sbfm